Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials

J I Silverberg, E L Simpson, M Ardeleanu, D Thaçi, S Barbarot, J Bagel, Z Chen, L Eckert, J Chao, A Korotzer, E Rizova, A B Rossi, Y Lu, N M H Graham, T Hultsch, G Pirozzi, B Akinlade, J I Silverberg, E L Simpson, M Ardeleanu, D Thaçi, S Barbarot, J Bagel, Z Chen, L Eckert, J Chao, A Korotzer, E Rizova, A B Rossi, Y Lu, N M H Graham, T Hultsch, G Pirozzi, B Akinlade

Abstract

Background: In the U.S.A., an Investigator's Global Assessment (IGA) score of ≤ 1 (clear or almost clear skin) has been the standard measure in regulatory outcomes for registration clinical trials in atopic dermatitis (AD), including those supporting the recent approval of dupilumab.

Objectives: To evaluate the treatment effect of dupilumab in patients with IGA > 1 at the end of treatment, using other validated outcome measures for AD signs, symptoms and quality of life.

Methods: LIBERTY AD SOLO 1 and 2 were two 16-week, randomized, double-blind trials enrolling adult patients with moderate-to-severe AD (IGA ≥ 3) inadequately controlled with topical treatment. We performed a post hoc analysis in patients receiving dupilumab 300 mg every 2 weeks (q2w) or placebo. Outcome measures in patients with IGA > 1 included Eczema Area and Severity Index (EASI), pruritus numerical rating scale (NRS), affected body surface area (BSA), Patient-Oriented Eczema Measure (POEM) and Dermatology Life Quality Index (DLQI). The trials were registered at ClinicalTrials.gov: NCT02277743 and NCT02277769.

Results: At week 16, 278 of 449 dupilumab q2w-treated patients (median age 36·0 years) and 396 of 443 placebo-treated patients had IGA > 1. Among patients with IGA > 1 at week 16, dupilumab significantly improved several outcome measures compared with placebo: EASI (-48·9% vs. -11·3%, P < 0·001), pruritus NRS (-35·2% vs. -9·1%, P < 0·001), affected BSA (-23·1% vs. -4·5%, P < 0·001), POEM score ≥ 4-point improvement (57·4% vs. 21·0%, P < 0·001) and DLQI score ≥ 4-point improvement (59·3% vs. 24·4%, P < 0·001).

Conclusions: In patients with IGA > 1 at week 16, dupilumab induced statistically significant benefits in multiple validated outcome measures compared with placebo. The IGA ≤ 1 end point significantly underestimates clinically relevant dupilumab treatment effects.

© 2019 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.

Figures

Figure 1
Figure 1
Outcomes in patients with Investigator's Global Assessment > 1 treated with dupilumab or placebo. (a) Percentage change from baseline to week 16 in Eczema Area and Severity Index (EASI) total score. (b, c) Proportions of patients who achieved ≥ 75% improvement in EASI (EASI 75) (b) or EASI 50 (c) at week 16. (d) Percentage change from baseline to week 16 in peak pruritus numerical rating scale (NRS) score. (e) Proportion of body surface area (BSA) affected by atopic dermatitis (AD). Error bars indicate standard error (SE). LOCF, last observation carried forward; LS, least squares; q2w, every 2 weeks. *P < 0·001 vs. placebo.
Figure 2
Figure 2
Outcomes in patients with Investigator's Global Assessment > 1 treated with dupilumab or placebo. (a) Change from baseline to week 16 in Dermatology Life Quality Index (DLQI) total score. (b) Proportion of patients with ≥ 4‐point reduction in DLQI score from baseline. (c) Change from baseline to week 16 in Patient‐Oriented Eczema Measure (POEM) score. (d) Proportion of patients with ≥ 4‐point reduction in POEM score from baseline. Error bars indicate the standard error. LOCF, last observation carried forward; LS, least squares; q2w, every 2 weeks. *P < 0·001 vs. placebo.
Figure 3
Figure 3
Illustration of a patient who improved from Investigator's Global Assessment (IGA) 4 (severe) at baseline to IGA 2 (mild) after 16 weeks of dupilumab treatment. Change in IGA score was accompanied by clinically meaningful improvement in BSA, symptoms (sleep, pruritus, POEM) and quality of life. BSA, body surface area; DLQI, Dermatitis Life Quality Index; EASI, Eczema Area and Severity Index; POEM, Patient‐Oriented Eczema Measure.

References

    1. Futamura M, Leshem YA, Thomas KS et al A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: many options, no standards. J Am Acad Dermatol 2016; 74:288–94.
    1. Chalmers JR, Schmitt J, Apfelbacher C et al Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME). Br J Dermatol 2014; 171:1318–25.
    1. Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005; 64 (Suppl. II):ii65–8.
    1. MacDonald LE, Karow M, Stevens S et al Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. Proc Natl Acad Sci U S A 2014; 111:5147–52.
    1. Murphy AJ, Macdonald LE, Stevens S et al Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci U S A 2014; 111:5153–8.
    1. Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL‐4/IL‐13 pathway in atopic diseases. Expert Rev Clin Immunol 2017; 13:425–37.
    1. Simpson EL, Bieber T, Guttman‐Yassky E et al Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375:2335–48.
    1. Blauvelt A, de Bruin‐Weller M, Gooderham M et al Long‐term management of moderate‐to‐severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1‐year, randomised, double‐blinded, placebo‐controlled, phase 3 trial. Lancet 2017; 389:2287–303.
    1. de Bruin‐Weller M, Thaçi D, Smith CH et al Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo‐controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol 2018; 178:1083–101.
    1. Wenzel S, Castro M, Corren J et al Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium‐to‐high‐dose inhaled corticosteroids plus a long‐acting β2 agonist: a randomised double‐blind placebo‐controlled pivotal phase 2b dose‐ranging trial. Lancet 2016; 388:31–44.
    1. Castro M, Corren J, Pavord I et al Dupilumab efficacy and safety in moderate‐to‐severe uncontrolled asthma. N Engl J Med 2018; 378:2486–96.
    1. Rabe K, Nair P, Brusselle G et al Efficacy and safety of dupilumab in glucocorticoid‐dependent severe asthma. N Engl J Med 2018; 378:2475–85.
    1. Bachert C, Mannent L, Naclerio RM et al Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA 2016; 315:469–79.
    1. Hirano I, Dellon ES, Hamilton JD et al Dupilumab efficacy and safety in adult patients with active eosinophilic oesophagitis: a randomised double‐blind placebo‐controlled phase 2 trial. United Eur Gastroenterol J 2017; 5:1138–50.
    1. Barbier N, Paul C, Luger T et al Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. Br J Dermatol 2004; 150:96–102.
    1. International Eczema Council . Validated Investigator Global Assessment Scale for Atopic Dermatitis (vIGA‐AD™). Available at: (last accessed 19 February 2019).

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa